Erythropoietin:
the signal behind red cells.

Red blood cells are specialized for transporting oxygen from the lungs to tissues. Their hemoglobin molecules bind and release oxygen, supporting aerobic metabolism throughout the body. Mature human erythrocytes lack nuclei and have a finite circulating lifespan, making continuous replacement necessary.

Erythropoietin (EPO) is a glycoprotein hormone essential for maintaining appropriate red blood cell production. EPO primarily supports the survival and expansion of responsive erythroid progenitors rather than directly converting mature blood cells into erythrocytes.

Its production is connected to the body's oxygen needs. When oxygen delivery becomes inadequate, EPO production can rise, promoting erythroid activity in the marrow. Over time, the resulting change in red cell mass can improve oxygen-carrying capacity.

Why the kidney
acts as an oxygen sensor.

In healthy adults, the kidney is the major physiological source of circulating EPO. Specialized fibroblast-like interstitial cells located near renal tubules are responsible for much of this production. They are often described as renal EPO-producing cells, or REPCs.

These cells respond to local oxygen availability through molecular pathways that regulate EPO gene transcription. Their EPO-producing activity can increase during hypoxia and decrease when oxygen availability improves.

The liver is an important source of EPO during fetal development and can contribute to production under certain adult physiological or pathological conditions. Nevertheless, normal adult EPO regulation is strongly kidney-dependent.

The distinction matters in kidney disease, where reduced or inappropriate EPO production can contribute to anemia even when the marrow retains the capacity to generate red cells.

The HIF–PHD–VHL
molecular switch.

The hypoxia-inducible factor pathway enables cells to adapt gene expression in response to oxygen availability. HIF proteins include an oxygen-sensitive alpha subunit and a constitutively available beta partner, also called ARNT.

Under oxygen-replete conditions, prolyl hydroxylase domain enzymes (PHDs) hydroxylate specific proline residues on HIF-alpha proteins. This permits recognition by the von Hippel–Lindau protein, part of an ubiquitin ligase complex, leading to proteasomal degradation.

When oxygen availability decreases, PHD-mediated hydroxylation becomes less efficient. HIF-alpha can accumulate, associate with HIF-beta and regulate hypoxia-responsive gene expression. In renal EPO-producing cells, HIF-2α, encoded by EPAS1, is particularly important for EPO induction.

HIF-1α and HIF-2α have overlapping and distinct functions. Both contribute to hypoxia responses, but HIF-2α has a particularly well-established role in adult renal EPO production.

How low oxygen
becomes a hormone signal.

Systemic oxygen stress can arise from reduced hemoglobin concentration, impaired oxygen availability or altered oxygen delivery. Renal oxygen-sensing pathways translate relevant tissue conditions into changes in EPO gene expression.

When hypoxia stabilizes HIF-2α in appropriate EPO-producing cells, transcriptional activation raises EPO synthesis. Secreted EPO enters the circulation and reaches the bone marrow, where responsive erythroid cells express the erythropoietin receptor.

An effective erythropoietic response unfolds over days and longer periods, rather than instantaneously. As red cell production and oxygen transport increase, the original hypoxic drive may diminish and EPO expression can decline.

The response is not determined by ambient oxygen concentration alone. Hemoglobin, blood flow, pulmonary function, kidney status and metabolic demand all influence tissue oxygen delivery and the integrated response.

EPOR, JAK2 and STAT5:
survival signaling.

EPO acts through its cell-surface receptor, EPOR, expressed by erythroid progenitors. EPOR belongs to the cytokine receptor family and associates with the intracellular tyrosine kinase JAK2. The receptor does not possess intrinsic kinase activity.

EPO binding promotes signaling complex rearrangement and JAK2 activation. This initiates phosphorylation events and recruits downstream effectors, including the transcription factor STAT5. Activated STAT5 contributes to gene programs that support erythroid cell survival and differentiation.

Anti-apoptotic signaling is especially relevant at EPO-responsive progenitor stages. EPO helps preserve erythroid cells that might otherwise undergo programmed cell death, enabling appropriate expansion and maturation.

EPOR signaling is not limited to STAT5. Additional pathways, including PI3K–AKT and MAP kinase-related cascades, participate in erythroid cellular responses depending on developmental context.

From progenitors
to red blood cells.

Erythropoiesis begins with hematopoietic progenitors that acquire progressively more restricted erythroid potential. Classical colony-assay terminology includes burst-forming unit–erythroid (BFU-E) and colony-forming unit–erythroid (CFU-E) populations.

EPO responsiveness becomes especially important in later erythroid progenitors, notably around the CFU-E and early erythroblast stages. Subsequent differentiation involves hemoglobin synthesis, reduction in cell size, nuclear condensation and eventual enucleation.

Enucleated reticulocytes undergo further maturation before becoming circulating erythrocytes. The maturation process depends on a combination of transcriptional regulators, iron supply, cellular metabolism and interactions with marrow support cells.

For a deeper account of these stages, see our Erythropoiesis educational guide.

More erythropoiesis
requires more iron.

Increasing erythroid cell production creates additional demand for iron, which is essential for hemoglobin synthesis. The physiological response to hypoxia therefore requires coordination between erythropoietin signaling and systemic iron availability.

Iron is transported through the circulation primarily bound to transferrin. Developing erythroblasts acquire transferrin-bound iron through receptor-mediated uptake and use it for heme synthesis. Insufficient available iron can limit hemoglobin production even when EPO signaling is elevated.

The liver-derived hormone hepcidin plays a central role in systemic iron regulation by controlling ferroportin, an iron export protein. Active erythropoiesis can stimulate erythroblasts to produce erythroferrone, which suppresses hepcidin signaling and facilitates iron availability.

Hypoxia at altitude:
an adaptive response.

High-altitude environments expose individuals to reduced atmospheric oxygen partial pressure. Acute exposure can stimulate physiological responses that include increased ventilation and changes in EPO production.

EPO responses may contribute to increased red blood cell production during acclimatization, but the degree and persistence of erythrocytosis vary. Excessive increases in hematocrit can also create physiological disadvantages.

Population studies have identified genetic variants affecting the oxygen-sensing pathway, including EPAS1-related variation, associated with adaptation to high-altitude environments. Such findings illustrate that effective adaptation does not simply require maximizing EPO or red blood cell mass.

Adaptation involves integrated changes across respiratory, cardiovascular, metabolic and hematopoietic systems. Their effects depend on the duration of exposure, inherited variation and individual physiological context.

When the feedback
system fails.

Disruption of oxygen-dependent erythropoiesis can contribute to anemia or excessive red cell production. The underlying mechanisms differ: some conditions reduce EPO production, some limit iron availability, and others alter erythroid cell responsiveness.

In chronic kidney disease, impaired renal EPO synthesis is one important contributor to anemia. Inflammation, iron restriction and reduced red blood cell survival may also contribute. The relative importance of each mechanism differs between patients.

Erythrocytosis can occur with sustained hypoxic stimuli, altered oxygen-sensing pathways or cell-intrinsic erythroid abnormalities. For example, polycythemia vera is a clonal myeloproliferative neoplasm commonly associated with acquired JAK2 mutations and is not simply the consequence of excessive renal EPO.

More detail is available in our Hematologic Diseases educational resource.

Oxygen sensing meets
modern biotechnology.

The discovery of EPO regulation and the HIF pathway transformed understanding of systemic oxygen homeostasis. It also enabled important applications in recombinant protein production, experimental hematology, molecular diagnostics and therapeutic research.

Recombinant human erythropoietin is a well-established biopharmaceutical used in selected clinical settings. Its development demonstrated how identification of a physiological hormone could support targeted treatment approaches, while also revealing the importance of careful safety monitoring.

Research into prolyl hydroxylases has led to HIF-PH inhibitors, which modulate oxygen-sensing pathways to increase endogenous EPO production and affect iron regulation. Their authorization, indications and precautions differ across jurisdictions, and their use requires appropriate clinical oversight.

In experimental biotechnology, investigators use erythroid cell differentiation models, flow cytometry, gene expression profiling, receptor signaling assays and oxygen-controlled culture systems to investigate erythropoiesis.

Emerging single-cell and spatial approaches can help characterize erythroid development and the marrow environments that support it. Gene editing and genetically defined cell models also provide opportunities to examine disease- associated changes in oxygen sensing and red blood cell development.

The central lesson is that red blood cell production depends on a coordinated system: oxygen detection, hormonal signaling, functional erythroid progenitors and adequate iron availability. Understanding these interactions connects fundamental physiology with contemporary hematology and biotechnology.